Research Article
Dementia and Alzheimer‘s disease: A new direction. The 2010 Jay L. Foster Memorial Lecture

Lewis H. Kuller and Oscar L. Lopez

Alzheimer`s & Dementia, 2011, 7(5), 540-550. DOI: 10.1016/j.jalz.2011.05.901

Abstract

Background The modern era of Alzheimer‘s disease (AD) research began in the early 1980s with the establishment of AD research centers and expanded research programs at the National Institute on Aging. Methods Over the past 30 years, there has been success in defining criteria for AD and dementia, association of important genetic disorders related to premature dementia in families, the association of apolipoprotein-E4, and measurement of incidence and prevalence and selected risk factors. However, prevention and treatment have been elusive. Results The development of new technologies, especially magnetic resonance imaging, positron emission tomography to measure amyloid in vivo in the brain and glucose metabolism, cerebrospinal fluid examination, better genetic markers, large-scale longitudinal epidemiology studies, and preventive clinical trials has rapidly begun a new era of research that offers opportunities to better understand etiology, that is, determinants of amyloid biology in the brain, neurofibrillary tangles, synaptic loss, and dementia. Conclusions There are three major hypotheses related to dementia: amyloid deposition and secondary synaptic loss as a unique disease, vascular injury, and ”aging.“ New research must be hypothesis-driven and lead to testable approaches for treatment and prevention.

ASCI-ID: 285-165

View Fulltext

Similar Articles


Fluorodeoxyglucose positron emission tomography of mild cognitive impairment with clinical follow-up at 3 years

Alzheimer`s & Dementia, 2010, 6(4), 326-333. DOI: 10.1016/j.jalz.2009.09.005

Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” A national registry on aging

Alzheimer`s & Dementia, 2009, 5(2), 105-107. DOI: 10.1016/j.jalz.2009.01.010

The epidemiology of Alzheimer‘s disease: Laying the foundation for drug design, conduct, and analysis of clinical trials

Alzheimer`s & Dementia, 2012, 8(3), 237-242. DOI: 10.1016/j.jalz.2011.12.005

A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging

Alzheimer`s & Dementia, 2012, 8(5), 381-388. DOI: 10.1016/j.jalz.2011.10.005

Review of selected databases of longitudinal aging studies

Alzheimer`s & Dementia, 2012, 8(6), 584-589. DOI: 10.1016/j.jalz.2011.09.232

Alzheimer's disease pathology does not mediate the association between depressive symptoms and subsequent cognitive decline

Alzheimer`s & Dementia, 2013, 9(3), 318-325. DOI: 10.1016/j.jalz.2011.11.009

The Alzheimer’s Disease Neuroimaging Initiative: Progress report and future plans

Alzheimer`s & Dementia, 2010, 6(3), 202-211. DOI: 10.1016/j.jalz.2010.03.007

Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses

Alzheimer`s & Dementia, 2010, 6(2), 104-109. DOI: 10.1016/j.jalz.2009.12.005

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer‘s Association Research Roundtable Workgroup

Alzheimer`s & Dementia, 2011, 7(4), 367-385. DOI: 10.1016/j.jalz.2011.05.2351

Anesthesia in presymptomatic Alzheimer‘s disease: A study using the triple-transgenic mouse model

Alzheimer`s & Dementia, 2011, 7(5), 521-531. DOI: 10.1016/j.jalz.2010.10.003

Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels

Alzheimer`s & Dementia, 2012, 8(4), 295-303. DOI: 10.1016/j.jalz.2011.05.900

Physician outpatient contacts and hospitalizations among cognitively impaired elderly

Alzheimer`s & Dementia, 2009, 5(1), 30-42. DOI: 10.1016/j.jalz.2008.05.2493

Dementia literacy: Recognition and beliefs on dementia of the Australian public

Alzheimer`s & Dementia, 2009, 5(1), 43-49. DOI: 10.1016/j.jalz.2008.03.011

Associations among measures of awareness of cognitive deficits in dementia

Alzheimer`s & Dementia, 2010, 6(4), 312-318. DOI: 10.1016/j.jalz.2009.06.005

A roadmap for the prevention of dementia II: Leon Thal Symposium 2008

Alzheimer`s & Dementia, 2009, 5(2), 85-92. DOI: 10.1016/j.jalz.2009.01.021

Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” A national registry on aging

Alzheimer`s & Dementia, 2009, 5(2), 105-107. DOI: 10.1016/j.jalz.2009.01.010

Commentary on `A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.` Establishing a national biomarker database: Utility and incentives

Alzheimer`s & Dementia, 2009, 5(2), 108-113. DOI: 10.1016/j.jalz.2009.01.015

Commentary on `A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.` Facilitating Alzheimer's disease drug development in the United States

Alzheimer`s & Dementia, 2009, 5(2), 125-127. DOI: 10.1016/j.jalz.2009.01.005

Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” A national registry to identify a cohort for Alzheimer's disease prevention studies

Alzheimer`s & Dementia, 2009, 5(2), 128-129. DOI: 10.1016/j.jalz.2009.01.018

Commentary on `A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.` Alzheimer's disease translational research programs at the National Institute on Aging

Alzheimer`s & Dementia, 2009, 5(2), 130-132.

Commentary on ”map for the prevention of dementia II: Leon Thal Symposium 2008.” ”Big Asks”: What can be changed to increase and speed progress on Alzheimer's disease research and treatment?

Alzheimer`s & Dementia, 2009, 5(2), 137-139. DOI: 10.1016/j.jalz.2009.01.003

Commentary on ”A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“ A proposal to increase participation in Alzheimer's disease clinical trials

Alzheimer`s & Dementia, 2009, 5(2), 140-142. DOI: 10.1016/j.jalz.2009.01.004

Commentary on ”A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.“ Rationale and recommendations for first evaluating anti-Alzheimer's disease medications in acute brain injury patients

Alzheimer`s & Dementia, 2009, 5(2), 143-146. DOI: 10.1016/j.jalz.2009.01.013

Commentary on ”A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.“ Who may benefit from disease-modifying studies in Alzheimer's disease?

Alzheimer`s & Dementia, 2009, 5(2), 147-148. DOI: 10.1016/j.jalz.2009.01.007

Commentary on ”A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.“ Primary prevention of dementia in Alzheimer's disease: A perspective from prevention research in cardiovascular disease and stroke

Alzheimer`s & Dementia, 2009, 5(2), 149-153. DOI: 10.1016/j.jalz.2009.01.012

Commentary on ”A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.“ Primary prevention of dementia in Alzheimer's disease: A perspective from prevention research in cardiovascular disease and stroke

Alzheimer`s & Dementia, 2009, 5(2), 149-153. DOI: 10.1016/j.jalz.2009.01.012

Commentary on ”A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“ Subjective cognitive impairment as an antecedent of Alzheimer's dementia: Policy import

Alzheimer`s & Dementia, 2009, 5(2), 154-156. DOI: 10.1016/j.jalz.2009.01.011

Commentary on ”A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“ Subjective cognitive impairment as an antecedent of Alzheimer's dementia: Policy import

Alzheimer`s & Dementia, 2009, 5(2), 154-156. DOI: 10.1016/j.jalz.2009.01.011

Commentary on ”A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“ Comments from abroad

Alzheimer`s & Dementia, 2009, 5(2), 157-158. DOI: 10.1016/j.jalz.2009.01.009

Commentary on ” A roadmap for the prevention of dementia II: Leon Thal symposium 2008.“ The megacommunity approach to Alzheimer's disease

Alzheimer`s & Dementia, 2009, 5(2), 163-165. DOI: 10.1016/j.jalz.2009.02.002

Commentary on ” A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“ Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: Opportunities and challenges

Alzheimer`s & Dementia, 2009, 5(2), 166-171. DOI: 10.1016/j.jalz.2008.12.002

Commentary on ”A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“A federally funded corporation for the prevention and treatment of cognitive impairment and brain aging

Alzheimer`s & Dementia, 2009, 5(2), 172-179. DOI: 10.1016/j.jalz.2009.01.023

Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old

Alzheimer`s & Dementia, 2009, 5(4), 318-323. DOI: 10.1016/j.jalz.2009.04.1230

Cognitive performance and informant reports in the diagnosis of cognitive impairment and dementia in African Americans and whites

Alzheimer`s & Dementia, 2009, 5(6), 445-453. DOI: 10.1016/j.jalz.2009.04.1234

Closing the dementia care gap: Can referral to Alzheimer's Association chapters help?

Alzheimer`s & Dementia, 2009, 5(6), 498-502. DOI: 10.1016/j.jalz.2009.01.024

Outcome over seven years of healthy adults with and without subjective cognitive impairment

Alzheimer`s & Dementia, 2010, 6(1), 11-24. DOI: 10.1016/j.jalz.2009.10.002

White matter integrity and cortical metabolic associations in aging and dementia

Alzheimer`s & Dementia, 2010, 6(1), 54-62. DOI: 10.1016/j.jalz.2009.04.1228

Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis

Alzheimer`s & Dementia, 2010, 6(1), 70-74. DOI: 10.1016/j.jalz.2009.04.1231

Early dementia diagnosis and the risk of suicide and euthanasia

Alzheimer`s & Dementia, 2010, 6(1), 75-82. DOI: 10.1016/j.jalz.2009.04.1229

The worldwide societal costs of dementia: Estimates for 2009

Alzheimer`s & Dementia, 2010, 6(2), 98-103. DOI: 10.1016/j.jalz.2010.01.010

A European perspective on population studies of dementia

Alzheimer`s & Dementia, 2011, 7(1), 3-9. DOI: 10.1016/j.jalz.2010.12.003

Counting dementia: There is no one ”best“ way

Alzheimer`s & Dementia, 2011, 7(1), 10-14. DOI: 10.1016/j.jalz.2010.11.003

Operationalizing diagnostic criteria for Alzheimer‘s disease and other age-related cognitive impairment–Part 2

Alzheimer`s & Dementia, 2011, 7(1), 35-52. DOI: 10.1016/j.jalz.2010.12.002

Sources of variability in estimates of the prevalence of Alzheimer‘s disease in the United States

Alzheimer`s & Dementia, 2011, 7(1), 74-79. DOI: 10.1016/j.jalz.2010.11.006

Serum homocysteine and dementia: Meta-analysis of eight cohort studies including 8669 participants

Alzheimer`s & Dementia, 2011, 7(4), 412-417. DOI: 10.1016/j.jalz.2010.08.234

How golden is the gold standard of neuropathology in dementia?

Alzheimer`s & Dementia, 2011, 7(4), 486-489. DOI: 10.1016/j.jalz.2011.04.011

Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer‘s disease patients

Alzheimer`s & Dementia, 2011, 7(5), 493-500. DOI: 10.1016/j.jalz.2011.01.004

Frequency of Alzheimer‘s disease pathology at autopsy in patients with clinical normal pressure hydrocephalus

Alzheimer`s & Dementia, 2011, 7(5), 509-513. DOI: 10.1016/j.jalz.2010.12.008

Videoconference diagnosis and management of Choctaw Indian dementia patients

Alzheimer`s & Dementia, 2011, 7(6), 562-566. DOI: 10.1016/j.jalz.2011.02.006

Predictors of suicide in patients with dementia

Alzheimer`s & Dementia, 2011, 7(6), 567-573. DOI: 10.1016/j.jalz.2011.01.006

Functional deficits among patients with mild cognitive impairment

Alzheimer`s & Dementia, 2011, 7(6), 611-614. DOI: 10.1016/j.jalz.2010.12.011

Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease

Alzheimer`s & Dementia, 2012, 8(1), 51-59. DOI: 10.1016/j.jalz.2011.06.003

Psychosocial stress at work is associated with increased dementia risk in late life

Alzheimer`s & Dementia, 2012, 8(2), 114-120. DOI: 10.1016/j.jalz.2011.03.001

The epidemiology of Alzheimer‘s disease: Laying the foundation for drug design, conduct, and analysis of clinical trials

Alzheimer`s & Dementia, 2012, 8(3), 237-242. DOI: 10.1016/j.jalz.2011.12.005

Some evolutionary perspectives on Alzheimer‘s disease pathogenesis and pathology

Alzheimer`s & Dementia, 2012, 8(4), 343-351. DOI: 10.1016/j.jalz.2011.05.2408

Analysis of case management programs for patients with dementia: A systematic review

Alzheimer`s & Dementia, 2012, 8(5), 426-436. DOI: 10.1016/j.jalz.2011.06.004

Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus

Alzheimer`s & Dementia, 2012, 8(5), 437-444. DOI: 10.1016/j.jalz.2011.05.2414

Impact of the Food and Drug Administration‘s antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings

Alzheimer`s & Dementia, 2012, 8(5), 453-457. DOI: 10.1016/j.jalz.2011.08.004

Predictive validity and diagnostic stability of mild cognitive impairment subtypes

Alzheimer`s & Dementia, 2012, 8(6), 553-559.

Association of environmental tobacco smoke with dementia and Alzheimer‘s disease among never smokers

Alzheimer`s & Dementia, 2012, 8(6), 590-595. DOI: 10.1016/j.jalz.2011.09.231

The worldwide economic impact of dementia 2010

Alzheimer`s & Dementia, 2013, 9(1), 1-11. DOI: 10.1016/j.jalz.2012.11.006

Apolipoprotein E genotype, dementia, and mortality in the oldest old: The 90+ Study

Alzheimer`s & Dementia, 2013, 9(1), 12-18. DOI: 10.1016/j.jalz.2011.12.004

Dementia and out-of-pocket spending on health care services

Alzheimer`s & Dementia, 2013, 9(1), 19-29. DOI: 10.1016/j.jalz.2011.11.003

The global prevalence of dementia: A systematic review and metaanalysis

Alzheimer`s & Dementia, 2013, 9(1), 63-75. DOI: 10.1016/j.jalz.2012.11.007

Vascular disease and dementias: Paradigm shifts to drive research in new directions

Alzheimer`s & Dementia, 2013, 9(1), 76-92. DOI: 10.1016/j.jalz.2012.02.007

Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging

Alzheimer`s & Dementia, 2013, 9(2), 113-122. DOI: 10.1016/j.jalz.2011.09.223

Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting

Alzheimer`s & Dementia, 2013, 9(2), 141-150. DOI: 10.1016/j.jalz.2012.09.011

Improving dementia care: The role of screening and detection of cognitive impairment

Alzheimer`s & Dementia, 2013, 9(2), 151-159. DOI: 10.1016/j.jalz.2012.08.008

A prediction model to calculate probability of Alzheimer‘s disease using cerebrospinal fluid biomarkers

Alzheimer`s & Dementia, 2013, 9(3), 262-268. DOI: 10.1016/j.jalz.2012.01.010

Mild cognitive impairment in a community sample: The Sydney Memory and Ageing Study

Alzheimer`s & Dementia, 2013, 9(3), 310-317. DOI: 10.1016/j.jalz.2011.11.010

Prevalence of mild cognitive impairment subtypes in patients attending a memory outpatient clinic—comparison of two modes of mild cognitive impairment classification. Results of the Vienna Conversion to Dementia Study

Alzheimer`s & Dementia, 2013, 9(4), 366-376. DOI: 10.1016/j.jalz.2011.12.009

Long–term anticholinergic use and the aging brain

Alzheimer`s & Dementia, 2013, 9(4), 377-385. DOI: 10.1016/j.jalz.2012.02.005

β-Site amyloid precursor protein–cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau

Alzheimer`s & Dementia, 2013, 9(4), 386-391. DOI: 10.1016/j.jalz.2012.01.015

Risk of Alzheimer's disease incidence attributable to vascular disease in the population

Alzheimer`s & Dementia, 2011, 7(3), 356-360. DOI: 10.1016/j.jalz.2010.12.004

Mild cognitive impairment: Disparity of incidence and prevalence estimates

Alzheimer`s & Dementia, 2012, 8(1), 14-21. DOI: 10.1016/j.jalz.2011.01.002

The epidemiology of Alzheimer‘s disease: Laying the foundation for drug design, conduct, and analysis of clinical trials

Alzheimer`s & Dementia, 2012, 8(3), 237-242. DOI: 10.1016/j.jalz.2011.12.005

Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies

Alzheimer`s & Dementia, 2012, 8(5), 407-416. DOI: 10.1016/j.jalz.2011.05.2413

Vascular risk factors, apolipoprotein E, and hippocampal decline on magnetic resonance imaging over a 10-year follow-up

Alzheimer`s & Dementia, 2012, 8(5), 417-425. DOI: 10.1016/j.jalz.2011.07.005

No association between gain in body mass index across the life course and midlife cognitive function and cognitive reserve–The 1946 British birth cohort study

Alzheimer`s & Dementia, 2012, 8(6), 470-482. DOI: 10.1016/j.jalz.2011.09.228

The global prevalence of dementia: A systematic review and metaanalysis

Alzheimer`s & Dementia, 2013, 9(1), 63-75. DOI: 10.1016/j.jalz.2012.11.007

Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: The ARIC MRI Study

Alzheimer`s & Dementia, 2009, 5(3), 207-214. DOI: 10.1016/j.jalz.2009.01.027

Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus

Alzheimer`s & Dementia, 2012, 8(5), 437-444. DOI: 10.1016/j.jalz.2011.05.2414

Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer‘s disease and related disorders

Alzheimer`s & Dementia, 2013, 9(1), 30-38. DOI: 10.1016/j.jalz.2012.11.002

Vascular disease and dementias: Paradigm shifts to drive research in new directions

Alzheimer`s & Dementia, 2013, 9(1), 76-92. DOI: 10.1016/j.jalz.2012.02.007